CLDX Valuation Metrics
FCF$-213.66M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Celldex Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Profile
Valuation (TTM)
Market Cap$2.09B
P/E-7.35
EV—
P/B3.96
Shares Out66.57M
P/Sales2408.99
Revenue$866000.00
EV/EBITDA—
Celldex Therapeutics Inc (CLDX) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →CLDX Valuation & Fair Value Analysis
Celldex Therapeutics Inc (CLDX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -7.35. Price-to-book ratio is 3.96. Price-to-sales ratio is 2408.99. PEG ratio is -0.16.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Celldex Therapeutics Inc's intrinsic value.